Stifel analyst Alex Thompson raised the firm’s price target on Spyre Therapeutics (SYRE) to $92 from $70 and keeps a Buy rating on the shares. The company’s upcoming readouts and other major updates expected in the TL1A space this year are expected by the firm to “shed light on the magnitude of the opportunity in IBD and beyond,” the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYRE:
- Spyre Therapeutics: Undervalued TL1A Leader With Accelerating Clinical Momentum and Near‑Term Catalysts
- Spyre Therapeutics completes recruitment for SKYWAY basket trial sub-study
- 3 ‘Strong Buy’ Stocks to Buy in Today’s Volatile Market, 2/23/2026, According to Top Analysts
- Spyre Therapeutics: Rich 12-Month Catalyst Calendar and Differentiated IBD Portfolio Support Buy Rating
- Spyre Therapeutics: Accelerating Clinical Momentum, Validated Combination Strategy, and Strong Cash Runway Support Buy Rating